Janssen-Cilag International NV (Janssen) has announced European Commission approval of an extended licence to the oral, once-daily medication Zytiga (abiraterone acetate).

The extended indication allows the use of Zytiga in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic, after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Janssen Europe, Middle-East, Africa, company group chairman Jane Griffiths said the decision by the European Commission marks another important step forward in the treatment of men with advanced castration-resistant prostate cancer.

"Treating men with ZYTIGA before they undergo chemotherapy has been shown to improve outcomes in many patients, both in terms of extending survival and in bettering quality of life," Griffiths added.

"The fact that ZYTIGA’s licence has now been extended to include this indication will help fill a critical medical need and, we hope, serve to significantly improve the lives of many men across Europe suffering from this disease."

See Also:

The decision was based on positive data from a randomised Phase III COU-AA-302 study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Study demonstrated a radiographic progression-free survival (rPFS) benefit and a strong trend in overall survival (OS) in the patient population.

Zytiga, with prednisone and prednisolone, was previously approved to treat men with mCRPC whose disease has progressed during or after a docetaxel-based chemotherapy regimen.

The recent approval allows all the eligible men to benefit from treatment with Zytiga earlier in the treatment pathway, according to the company.